{
  "drug_name": "Amiodarone",
  "url": "https://wikem.org/wiki/Amiodarone",
  "scraped_at": "2026-01-10T02:46:20.557373",
  "sections": {
    "General": "Type:\nAntiarrhythmics\nDosage Forms: injectable solution, tablet\nRoutes of Administration: IV, PO\nCommon Trade Names: Cordarone, Pacerone, Nexterone",
    "Adult_Dosing": "V-fib\n/\npulseless V-tach\nLoading dose = 300mg IV bolus followed by 150mg bolus PRN\nStable\nwide complex tachycardia\n(e.g. V-tach) or\nSVT\n150 mg in 100mL D5W over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)\n[1]\nThen 0.5 mg/min drip over next 18 hrs (540 mg total)\nOral dosage after IV infusion is 400 -800 mg PO daily",
    "Special_Populations": "Pregnancy Rating\n: D\nLactation Risk Categories\n: Unsafe\nRenal Dosing- no adjustment\nAdult\nPediatric\nHepatic Dosing- caution and consider dose decrease\nAdult\nPediatric",
    "Contraindications": "Allergy to class/drug\nIodine or shellfish allergy\nPregnancy",
    "Adverse_Reactions": "Amiodarone\nAdverse Effects\nBradycardia\nHypotension with older solvent-based formulation. Uncommon with newer aqueous formulation.\nProlonged QT\nThyrotoxicosis\n[2]\nBetween 5-20% of patients treated with amiodarone have thyrotoxicosis (higher in areas of iodine deficiency)\nIodine-induced hyperthyroidism\nIt is thought that the iodine load may unmask hyperthyroidism in patients with multinodular goiter and subclinical Gravesâ€™ disease\nDrug-induced destructive thyroiditis\nMore commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone.\nAmiodarone pulmonary toxicity\nHyperpigmentation rash",
    "Pharmacology": "Half-life: 58 days\nMetabolism: Liver extensively\nExcretion: Bile primarily\nMechanism of Action\nClass III - Inhibits potassium channels\nImpairs SA and AV node conduction\nDecreases automaticity\nProlongs refractory period in accessory pathways\nAlso has class I & II properties"
  }
}